Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.
During #ASH18, we & our collaborators @seattlechildren’s research institute will highlight findings around Conversion of T-Effector Cells to Immunosuppressive T-Regulatory-like Cells By #CRISPR/Cas9-Mediated Integration of a FOXP3 Transgene. Abstract here: https://t.co/Vy6NkqdQAk
At the @MassBio Dinner on board #diversity this week w leaders from @jpmorgan, @NASA, #FrequencyTx @PolarisVC, Kaleido BioScience & Dimock Community Health Center. An illuminating and important conversation that we are pleased to be part of as we shape the future of our industry